Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2

Authors

Shadisadat Esmaeili[1]*, Katherine Owens[1], Joseph F. Standing[2,3], David M. Lowe[4,5], Shengyuan Zhang[2], James A. Watson[6,7], William H. K. Schilling[7,8], Jessica Wagoner[9], Stephen J. Polyak[9], Joshua T. Schiffer[1,10]

Affiliations

[1] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA.

[2] Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, UK

[3] Great Ormond Street Hospital for Children NHS Trust, London, UK

[4] Department of Clinical Immunology, Royal Free London NHS Foundation Trust, London, UK

[5] Institute of Immunity and Transplantation, University College London, London, UK

[6] Infectious Diseases Data Observatory, Oxford, UK

[7] Centre for Tropical Medicine and Global Health, Nuffield, Department of Medicine, University of Oxford, Oxford, UK

[8] Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand

[9] Department of Laboratory Medicine & Pathology, University of Washington; Seattle, WA, USA

[10] Department of Medicine, University of Washington; Seattle, WA, USA.

*Corresponding Author: sesmaeil@fredhutch.org

Abstract

Molnupiravir is an antiviral medicine that induces lethal copying errors during SARS-CoV-2 RNA replication. Molnupiravir reduced hospitalization in one pivotal trial by 50% and had variable effects on reducing viral RNA levels in three separate trials. We used mathematical models to simulate these trials and closely recapitulated their virologic outcomes. Model simulations suggest lower antiviral potency against pre-omicron SARS-CoV-2 variants than against omicron. We estimate that in vitro assays underestimate in vivo potency 7-8 fold against omicron variants. Our model suggests that because polymerase chain reaction detects molnupiravir mutated variants, the true reduction in non-mutated viral RNA is underestimated by ~0.5 $\log_{10}$ in the two trials conducted while omicron variants dominated. Viral area under the curve estimates differ significantly between non-mutated and mutated viral RNA. Our results reinforce past work suggesting that in vitro assays are unreliable for estimating in vivo antiviral drug potency and suggest that virologic endpoints for respiratory virus clinical trials should be catered to the drug mechanism of action.

Introduction

Molnupiravir is an antiviral prodrug that induces errors in the SARS-CoV-2 genome, which typically renders the virus unable to replicate further.[1] In the randomized double-blinded MOVe-OUT trial, which enrolled unvaccinated individuals when delta, mu, and gamma variants of concern (VOC) were circulating, molnupiravir reduced hospitalization by 50% and viral load after treatment (day 5) by 0.3 log relative to placebo.[2] In the platform adaptive PANORAMIC trial, which enrolled vaccinated individuals when omicron VOCs were circulating, hospitalization rates were only 1% in both arms, but molnupiravir lowered viral load after treatment by 0.94 $\log_{10}$ relative to usual care.[3] In the adaptive platform trial PLATCOV, which enrolled low-risk individuals when omicron VOCs were circulating, molnupiravir lowered viral load after treatment by 1.09 log relative to usual care.[4] Taken together, these trials demonstrate that molnupiravir has both clinical and virologic efficacy which varied across trials and viral variants.

Overall, use of molnupiravir has been lower than that of nirmatrelvir / ritonavir based on lower reduction in hospitalization in MOVe-OUT relative to the EPIC-HR trial for nirmatrelvir / ritonavir.[5] A concern has also been raised that molnupiravir's mechanism of action could generate novel mutants that persist after cessation of treatment,[6] and then spread in the population.[7] Nevertheless, the PANORAMIC and PLATCOV trial results suggest high potency, and molnupiravir is still considered in individuals in whom nirmatrelvir / ritonavir is contraindicated and in combination with other drugs in immunocompromised hosts.[8, 9] There is currently no explanation for the disparate antiviral effects in MOVe-OUT versus PANORAMIC and PLATCOV. Moreover, the fact that polymerase chain reaction (PCR) detects drug-altered viral RNA molecules[6] has not been considered in the analysis of trial outcomes. A study in ferrets highlights the potential importance of this effect: while molnupiravir and nirmatrelvir / ritonavir dramatically lowered levels of infectious SARA-CoV-2 titers, only nirmatrelvir / ritonavir lowered total viral RNA levels.[10]

We previously used clinical trial simulation to reproduce results from nirmatrelvir / ritonavir trials for SARS-CoV-2.[11, 12] We first validated a viral immune dynamic model (VID) against a very large prospective cohort of infections that included multiple VOCs.[12] We used sets of model parameters that reflect diverse virologic output to create simulated cohorts for the control arms of trials. We then integrated pharmacokinetic (PK) and pharmacodynamic (PD) models for nirmatrelvir / ritonavir with the VID models to simulate treatment arms.[11] This approach recapitulated mean viral load reduction in the EPIC-HR and PLATCOV trials, as well as individual viral load trajectories in PLATCOV. The validated model was then used to explain the high frequency of virologic and concurrent symptomatic rebound with use in the community,[13] despite very low levels of virologic and symptomatic rebound in the EPIC-HR trial.[14, 15] Model output suggests that extending therapy from 5 to 10 days would nearly eliminate rebound,[11] a result confirmed with modeling of separate data.[16]

Here we expand this approach to develop a new joint VID-PK-PD model to account for the unique mechanism of action of molnupiravir. We fit the model to results from the MOVe-OUT, PLATCOV and PANORAMIC trials. Our results suggest that quantitative viral PCR likely

94   underestimates the reduction in non-mutated viral RNA and therefore the true potency of
95   molnupiravir during omicron infections.
96

97   **Results**
98
Viral immune dynamic, pharmacokinetic and pharmacodynamic clinical trial simulation
models.
We previously described our viral immune dynamic (VID) model that was fit to diverse serial
viral loads from 1510 SARS-CoV-2 infected individuals in the National Basketball Association
cohort.[12, 17] The model assumes a finite number of susceptible cells and an eclipse phase delays
viral production by infected cells. In keeping with an early innate immune response, susceptible
cells become refractory to infection in the presence of infected cells but also revert to a
susceptible state at a constant rate. Infected cells are cleared by cytolysis and delayed acquired
immunity, which is activated in a time-dependent fashion **(Fig 1a)**. We used a mixed-effect
population approach implemented in Monolix to estimate model parameters.[18]
109

110
Fig 1. Schematic of the viral dynamic model and molnupiravir PK-PD model. (a) In the viral
dynamic model, S represents the susceptible cells, I_E is the eclipse infected cells, I_P is the productively
infected cells, V is the non-mutated viruses, and V_m is the mutated viruses as a result of treatment. The
productively infected cells are cleared by early and late T cell-mediated immune response at rates δ and
$m(t)$. β is the infectivity rate, ϕ is the rate of conversion of susceptible cells to refractory cells, and ρ is
the rate of reversion of the refractory cells to susceptible cells. productively infected cells produce viruses
at the rate π, and free viruses are cleared at the rate γ. **(b)** Two-compartmental PK model with oral
administration of the drug which models the amounts of the drug in gut tissue (A_{GI}), plasma (A_P), and the
respiratory tract (A_L). κ_a is the rate of absorption of the drug from gut to plasma, κ_{PL} and κ_{LP} are the rates
of transfer of the drug from plasma to the respiratory tract and back, and κ_{CL} is the rate at which the drug
clears from the body. Vol is the estimated plasma volume and C_P is the concentration of the drug in
plasma. $\epsilon(C_P)$ is the efficacy of the drug in converting produced viruses into mutated viruses.
123
To reproduce levels of molnupiravir, we used a two-compartment pharmacokinetic (PK) model
(Fig. 1b). Using Monolix and the mixed-effect population approach, we estimated parameter

values by fitting the model to the average plasma concentration of healthy subjects.[19] The model
closely recapitulated observed drug levels following multiple doses of 50, 100, 200, 300, 400,
600, and 800 mg given twice daily for five days (**Fig S1, Table S1**). The estimated value for the
transition rate from plasma to peripheral compartment (κ_{PL}) was dose-dependent in the form of
$\kappa_{PL} = \kappa_{PL,1}Dose^{\alpha}$. All other PK parameters were dose independent. For the pharmacodynamic
(PD) model, we assumed drug efficacy follows a Hill equation with respect to concentration. We
parameterized the model using in vitro efficacy data collected at different concentrations (details
in **Materials and Methods**, **Fig S2, Table S2**).[20]

We combined the VID and PKPD models by using treatment efficacy to convert non-mutated
virus to mutated virus, both of which are assumed to be detected with polymerase chain reaction
(PCR) assays, given the low probability of drug-induced mutations in the PCR primer region.
This assumption is based on the observed drug-induced mutation rate of approximately 1
mutation per 2000 base pairs.[21] Given the average length of most PCR primers of ~25 base pairs,
the chance of the primer remaining unmutated after treatment is $(1999/2000)^{25}$, or 98.76%. A
limitation of viral load data from the included clinical trials is that it lacks early pre-symptomatic
endpoints to estimate the viral expansion slope. To further train the model, we included omicron-
infected participants from the NBA cohort (n=1023) to inform rates of viral upslope in the
trials.[12] We first fit the combined model to individual viral load data from 149 low-risk,
symptomatic vaccinated participants infected with omicron VOCs in the PLATCOV trial (65
treated and 84 controls) and from 80 high-risk, symptomatic vaccinated participants infected
with omicron VOCs in the PANORAMIC trial (38 treated and 42 controls) (**Fig 2a, 2b, Fig S3,**
S4, S5, S6). We next fit the combined model to trial endpoint data (mean viral load drop from
baseline) reported in three randomized, controlled trials: PLATCOV (**Fig 3a, 4a-d**),[4]
PANORAMIC (**Fig 3b, 4e-h**),[3] and the MOVe-OUT trial with 1093 high-risk unvaccinated
symptomatic individuals infected with pre-omicron VOCs (549 treated + 544 placebo, **Fig 3c, 4i-**
k).[2] All model fitting was performed using Monolix with non-linear mixed effects approaches
described in the **Materials and Methods**.

Fig 2. Mathematical model fits of SARS-CoV-2 viral load over time to a subset of study participants in PLATCOV and PANORAMIC receiving no treatment (control) or molnupiravir. (a) Model fits to 9 control and 9 treatment participants in PLATCOV. **(b)** Model fits to 9 control and 9 treatment participants in PANORAMIC. **(c)** Individual estimates for potency adjustment factor (ratio of *in vivo : in vitro* EC50) in the two trials (center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range). The statistical comparison was performed using Mann-Whitney U-test.

Model fitting to individual viral load trajectories in PLATCOV and PANORAMIC.
For each participant, we defined the in vivo EC_{50} as the plasma drug concentration required to inhibit viral replication by 50% and the potency adjustment factor (paf) as the ratio between the in vivo and in vitro EC_{50}.[22, 23] To estimate the paf, we fit the combined VID-PKPD model to individual viral load data from both arms of the PLATCOV and PANORAMIC trials, as well as omicron infected individuals in the NBA cohort using the population mixed effect approach in Monolix. We achieved good model fit to individual viral load trajectories in the control and treatment arms of PLATCOV **(Fig 2a, Fig S3, S4)** and PANORAMIC **(Fig 2b, S5, S6)**. The model projected higher levels of total detected SARS-CoV-2 RNA in most participants relative to non-mutated viral RNA **(Fig 2a,b)**. We estimated a range of individual paf values with similar mean and median values estimated for both trials **(Fig 2c)**. These values suggest that in vivo potency of molnupiravir is on average 7-8 fold higher than estimates based on in vitro data. Each participant had an estimated paf less than one indicating that enhanced potency in vivo is necessary to accurately model the data.

Figure 3. Mean viral load reduction in three trials which are targets for model fitting: (a)
PLATCOV, including individuals with no prior risk factor infected by omicron variant, and enrolled
within 96 hours of symptom onset, **(b)** PANORAMIC, including individuals with prior risk factor
infected by omicron variant, and enrolled on average 2.5 days since symptom onset, and **(c)** MOVe-OUT,
including high-risk, unvaccinated individuals, infected by delta, mu, and gamma variants, and enrolled
within five days of symptom onset**.**

Model fit to trial virologic endpoint data from PLATCOV, PANORAMIC, and MOVe-OUT.

As a second approach, we assessed whether a virtual cohort strategy where control participants
are modeled using estimated parameter values from pre-existing cohorts can predict virologic
trial endpoints. This approach is necessary for situations where individual viral load data are not
available as with MOVe-OUT and demonstrates that the model can reproduce the primary
virologic endpoint of each study. We simulated virtual cohorts using the combined VID-PKPD
model and fit results to viral load decay from baseline in the three trials. For each trial arm, we
randomly selected 400 individuals from the NBA cohort with the closest matching viral variant,
symptom, and vaccine status and used their estimated individual viral dynamic parameters in
simulations. To address variability in timing of baseline viral load measurement relative to
infection, we randomly assigned all individuals an incubation period selected from a variant-
specific gamma distribution found in the literature.[24, 25] Treatment start day was randomly
selected from a distribution based on observed enrollment windows in the three trials. Due to the
lack of individual PK data, the same estimated population PK parameters were used for all
simulated treated individuals **(Table S1)**. PD parameters were randomly selected from a log-
normal distribution with estimated mean and standard error from in vitro assay results (**Table
S2**).

Our model closely reproduced kinetics of viral decay in the PLATCOV control **(Fig 3a, 4a)** and
treatment arms **(Fig 3a, 4b)** and estimated a paf=0.13 **(Fig 4c)** similar to our mean estimate using
individual fits **(Fig 2c)**. The model also predicted individual-level variability in virologic
responses observed in PLATCOV, including instances of increased viral load following therapy
(Fig 4d). We compared simulated and actual distributions of viral load change among trial
participants in the control and treatment arms. On most post-treatment days, simulated and actual
distributions were not statistically dissimilar. Wider distributions of observed versus simulated
viral load change were noted on post-randomization days 1 and 2 for control and treatment **(Fig
4d),** likely due to noise in viral load data from oral swabs: differences of 1–2 logs were often
noted between replicates collected from PLATCOV participants at equivalent timepoints,
particularly on days 1 and 2.[11]
212

213
Figure 4. Model fit to virologic trial outcomes for (a-d) PLATCOV, (e-h) PANORAMIC, (i-k)
MOVe-OUT. Results include **(a, e, i)** control groups, **(b, f, j)** treatment groups, **(d,h)** comparing
individual variability of data vs simulation in control and treatment arms, and **(c, g, k)** estimate for
potency adjustment factor. To only capture the effect of treatment and address potential identifiability
issues, data from the first seven days after baseline were used to estimate the paf. Therefore, the crossed-
out data points were not included in the calculation of the R^2.
220
Similarly, our model closely reproduced kinetics of viral decay in PANORAMIC in control **(Fig
3b, 4e)** and treatment arms **(Fig 3b, 4f)** and estimated a paf=0.19 **(Fig 4g)** similar to our mean
estimate using individual fits **(Fig 2c)**. The model also predicted individual-level variability in
virologic responses observed in PANORAMIC, including instances of increased viral load
following therapy **(Fig 4h)**. We compared simulated and actual distributions of viral load change
among trial participants in the control and treatment arms. On all post-treatment days other than
day 2 control, simulated and actual distributions were not statistically dissimilar **(Fig 4h).** This
likely indicates less noise in viral load data from nasopharyngeal swabs collected in
PANORAMIC relative to oral swabs in PLATCOV.
230

231 Finally, the model reproduced kinetics of viral decay in MOVe-OUT in control **(Fig 4i)** and
232 treatment arms **(Fig 4j)** but estimated a higher paf=2.64 **(Fig 4k).** The higher paf maps to the far
233 less substantial viral load reduction in MOVe-OUT relative to the other two trials which in turn
234 might be explained by less potency against pre-omicron variants which has been observed
235 experimentally.[26]
236
As a further validation step, we performed counterfactual simulations which assess viral kinetics
of control study participants assuming treatment and treatment participants assuming
placebo/usual care. Counterfactual control simulations slightly overestimated late viral loads for
PLATCOV **(Fig S7a)** and PANORAMIC **(Fig S8a)**. This may be because therapy suppresses
acquired immune responses, which is not captured in our model.[16] Counterfactual treatment
simulations fit the data well for PLATCOV **(Fig S7b)** and PANORAMIC **(Fig S8b)**. Simulations
occasionally predicted viral rebound following treatment **(Fig S7c,d and S8c,d).**
244
245

246
Figure 5. PCR underestimates the true reduction in non-mutated SARS-CoV-2 RNA in PLATCOV
and PANORAMIC. Simulated mean viral loads including non-mutated viral RNA in (a) PLATCOV, (b)
PANORAMIC and (c) MOVe-OUT. (d) Individual reduction at day 5 in the simulated control group
(blue), simulated total viral RNA (grey) and simulated non-mutated viral RNA (pink) in the three trials
showing no statistical difference between total and non-mutated viral RNA despite a lower median. (e)
Individual viral area under the curve from the start of the treatment through day 5 in the simulated control
group (blue), simulated total viral RNA (grey), and simulated non-mutated viral RNA (pink) in the three
trials showing a statistical difference between total and non-mutated viral RNA. Boxplots include the
interquartile range (IQR) with whiskers equaling 1.5 the IQR. (f) Table of mean viral load reductions in
the trials and simulations including the predicted mean difference in total versus mutated viral RNA.
257
258 **Estimates of reduction in fully mutated viruses versus non-mutated SARS-CoV-2 RNA.**

We used our optimized model with solved paf to project the trajectory of non-mutated viral RNA during treatment relative to values measured with PCR, which detects viral RNA with drug-induced mutations.[6] In PLATCOV **(Fig 5a,d,f)** and PANORAMIC **(Fig 5b,d,f)**, owing to higher drug potency, total SARS-CoV-2 viral RNA on treatment exceeded non-mutated viral RNA by ~0.48 and 0.59 log respectively, suggesting that measured endpoints underestimate the drug's true antiviral effect. However, these differences did not achieve statistical significance, perhaps because estimated total and non-mutated viral RNA levels converge at drug trough. In MOVe-OUT **(Fig 5c,d,f)**, there was no significant difference between total SARS-CoV-2 viral RNA on treatment and non-mutated viral RNA.

Figure 6. Relationship of drug pharmacokinetics and pharmacodynamics to in vivo potency and viral load reduction, comparing trial design. (a) Molnupiravir plasma concentration during five days of treatment with 800 mg molnupirvir given twice daily. The dashed lines mark the EC_{50} with different paf values which differ by trial. For paf = 0.13, drug levels are almost entirely above the EC_{50}. (b) Dynamic shifts in molnupiravir efficacy for different paf values which differ by trial. Efficacy only drops minimally at trough levels when paf is low (i.e. 0.14 and 0.13 in PLATCOV and PANORAMIC) but drops significantly at trough levels in MOVe-OUT. (c) Drug potency of SARS-CoV-2 antivirals according to trial. The in-vivo efficacy of molnupiravir in PLATCOV and PANORAMIC trials is close to the in vivo efficacy of nirmatrelvir/ritonavir in the PLATCOV trial and higher than EPIC-HR. MOVe-OUT potency is significantly lower due to a higher paf and higher in vivo EC50 value. (d) Simulated mean drops in total viral RNA from baseline relative to counterfactual placebo/usual care arms on day 5 in the three molnupiravir trials and two nirmatrelvir/ritonavir trials. (e) Simulated mean drops in non-mutated viral RNA from baseline relative to counterfactual placebo on day 5 in the three molnupiravir trials and two nirmatrelvir/ritonavir trials. In the molnupiravir trials, total viral RNA drops less than non-mutated viral RNA due to PCR detection of drug-mutated viral RNA. Total possible reduction in non-mutated SARS-CoV-2 RNA is less for MOVe-OUT than PLATCOV and PANORAMIC due to higher initial viral loads and lower values of detection in the trials.

In all 3 trials, the models suggest that non-mutated viral loads during treatment may be lowest at drug peak, reflecting the short plasma half-life of molnupiravir. Therefore, the cumulative effect of drug is best estimated with viral area under the curve (AUC) which accounts for highly variable drug activity over time due to short drug half-life. By this estimate, the reduction in non-mutated viral RNA far exceeds that of total measured viral RNA **(Fig 5e)**. In the case of MOVe-

OUT, this may explain why significant clinical benefit is associated with only a marginal reduction in observed decline in total viral RNA. This also suggests that there might be utility to measure viral load after drug peak and trough for agents with short half-life as viral loads may differ by a full order of magnitude according to drug level.

To mimic endpoints in PLATCOV, we estimated the slope of viral decay of the total viral RNA on and off-treatment as well as the non-mutated viral RNA by fitting a line to simulated data on days 0-5 after the start of the treatment. The median clearance half-life in our simulations of PLATCOV control and treatment arms reflected those observed in the trial **(Table S3).** Our results showed small differences (non-significant) between the clearance rates for the total versus the non-mutated viral RNA in the treated groups in PLATCOV and PANORAMIC (**Fig S9**).

Differences in trial participants and model parameters.
We also compared features of each trial as they related to model predictions by assessing the viral dynamic range in each trial **(Fig S10a)**. Control participants in PLATCOV had lower mean viral loads throughout the course of infection relative to PANORAMIC and MOVe-OUT **(Fig S10b)**. Given PLATCOV and PANORAMIC enrolled participants with the omicron variant, we surmise that these differences relate to demographic differences in study participant demographics, slightly shorter estimated time to treatment in PANORAMIC versus PLATCOV estimated by our model (t_0 in **Fig S11**), and/or characteristics of the PCR assay used in the studies. The trials also employed different limits of detection which impacted observed reductions in viral load **(Fig S10b).** Model parameters were largely equivalent between studies and between treatment and control arms, reflecting the flexibility of the model **(Fig S11)**. The parameter governing transition of susceptible cells to a refractory state was higher in PLATCOV relative to PANORAMIC which likely was necessary to achieve lower viral loads overall and may reflect the younger study participants **(Fig S11)**.

Antiviral potency, viral load assessment and trial design all impact observed antiviral reduction.
We next combined PK and PD models to assess the average efficacy of the drug during days 0-5 in all three trials **(Fig 6a,b)** and noted an efficacy of 53% in MOVe-OUT **(Fig 6c)**. The efficacy of molnupiravir in PLATCOV (94%) and PANORAMIC (95%) was similar to that of nirmatrelvir in PLATCOV (94%) and EPIC-HR (82%) owing to a much lower paf for molnupiravir relative to nirmatrelvir / ritonavir **(Fig 6c)**.

These potencies mapped to different reductions in viral load relative to placebo/usual care. Total viral RNA reduction in PANORMIC and PLATCOV exceeded that in MOVe-OUT owing to lower paf **(Fig 6d),** but also due to a larger viral dynamic range (defined as the distance from baseline viral load to the lower threshold PCR (LOD) **(Fig S10b)**), which allows for a greater observed reduction in viral load. PANORAMIC used LOD = 109 (imputed as 50), and PLATCOV had LOD≅18 (copies/ml), but MOVe-OUT had a higher LOD = 500 copies/ml. PANORAMIC also had much higher average starting viral loads (7.4 log10 (copies/ml)) versus PLATCOV (5.8 log10 copies/ml) and MOVe-OUT (6.8 log10 copies/ml) **(Fig S10b)**. Molnupiravir approached maximal possible total viral RNA reduction in PANORAMIC and PLATCOV, whereas protease inhibitors could still achieve greater viral load reduction at lower paf **(Fig 6d)** as recently observed with ensitrelvir.[27]

339
The greater possible reduction in total viral load for protease inhibitors relative to mutagenic
drugs like molnupiravir owes to different mechanisms of action. Model projected reductions in
non-mutated viral RNA reduction in PANORMIC and PLATCOV approximated viral load
reductions observed in EPIC-HR and PLATCOV on nirmatrelvir / ritonavir **(Fig 6e)**. This
suggests that PCR detection of mutated viruses underestimates true molnupiravir potency, and
that a more potent mutagenic agent could accrue further virologic benefit even if the total
reduction in viral RNA does not increase.
347
348 **Optimization of molnupiravir therapy to avoid viral rebound.**
349 Instances of viral rebound were observed in PLATCOV and PANORAMIC and have been
350 observed following molnupiravir treatment.[4, 28] We analyzed higher doses and prolonged therapy
351 and noted that as with nirmatrelvir, prolonging therapy is a better method to prevent rebound
352 than increasing dose **(Fig S12).**
353
354
355

Discussion

We recapitulated the virologic results of three clinical trials for molnupiravir with our combined clinical trial simulation VID-PK-PD models. Model output highlights key differences in viral load reduction between the trials and identifies mechanistic differences to explain this. The MOVe-OUT trial was associated with significantly less reduction in viral load between treatment and control arms than the other two trials. Accordingly, the average drug efficacy over the dosing interval (53%) was lower in this trial, and our estimate for paf was 2.64, signifying marginally lower potency in vivo than in vitro. This result is compatible with 0.4-fold lower median EC50 values for molnupiravir in vitro against omicron relative to prior variants,[26] though explanations other than viral variant cannot be ruled out. The higher paf in MOVe-OUT permitted drug troughs below the EC50, limiting potency throughout the dosing interval. In PLATCOV and PANORAMIC, our model suggests drug levels remain above the in vivo EC50 throughout the dosing interval though potency does fluctuate according to drug level.

The projected drug efficacy in PLATCOV and PANORAMIC was considerably higher (0.94 and 0.95, respectively), and the paf was estimated to be 0.14 and 0.13, indicating greater potency in vivo than in vitro. We have applied our clinical trial simulation technique to multiple drugs for SARS-CoV-2,[11] HSV-2,[22, 23] and HIV,[29] and this is the first time we have identified this trend. Allowing molnupiravir to be more potent in vivo in our modeling of PLATCOV and PANORAMIC was necessary to capture the much greater reduction in total viral RNA relative to off-treatment in these studies (1.09 log and 0.94 log respectively versus 0.3 log in MOVe-OUT).

A key outcome of our analysis is the prediction that SARS-CoV-2 PCR likely underestimates molnupiravir potency because it still detects drug-mutated viral RNA.[6] This appears to be most significant when antiviral potency is higher, as in PANORAMIC and PLATCOV, leading to a 0.48-0.59 log underestimation of reduction in non-mutated virus. Our results suggest that use of standard PCR for assessing SARS-CoV-2 levels may lead to underestimation of drug potency. Multi probe assays as have been used for the HIV reservoir may improve specificity for viruses that remain intact and replication competent.[30] Viral culture is potentially a useful metric but lacks sufficient sensitivity and precision and is too labor intensive to serve as a viable trial endpoint.[13] In the ferret model, molnupiravir lowered levels of culturable virus while not lowering total viral RNA levels relative to control.[10]

A further consideration of our analysis is selection of optimal virologic endpoints in clinical trials. The PLATCOV study demonstrates that viral clearance slope is an efficient and robust metric to identify potency after enrollment of a limited number of trial participants.[4] It is advantageous relative to viral load reduction as it incorporates all viral load data points in the analysis. We observed small non-statistically significant differences between clearance slopes of total versus non-mutated viral RNA in simulations of all three trials. However, we observed significant reductions in viral area under the curve during therapy in all three simulated trials, suggesting that this may be an even more sensitive trial endpoint. In viral dynamic models, viral AUC maps directly to surface area of total infected cells providing a mechanistic underpinning of why this may be a useful endpoint.[31, 32]

Our results suggest that viral loads may vary according to drug level given molnupiravir's short
plasma half-life. A sub-study within future trials comparing viral loads between drug trough and
peak would be useful for the field. This could validate our model's prediction that even small
reductions in viral RNA may be associated with substantial reductions in total viral AUC
particularly with a short half-life drug. Even minor reductions in viral load may be associated
with substantial clinical benefit in this case. These fluctuations may be less evident if the intra-
cellular half-life of the drug is longer or if PK measures in our model underestimate true drug
levels in PANORMIC due to older age or impaired renal clearance. Model accuracy would be
improved if viral load and PK data were available from the same patients in similar trials.
410
411 Another key practical outcome is that as for nirmatrelvir, extension of molnupiravir therapy to 10
412 days is likely to prevent rebound, though our simulations do not suggest any benefit from
413 increasing dose.[11] This suggests that prolonging therapy or using longer half-life agents is ideal
414 for treating SARS-CoV-2.[33]
415
Each trial represented a unique set of issues for model fitting. In MOVe-OUT, because the mean
viral kinetics curve of treatment arm differed only slightly from that of the control arm, the
model without drug provided reasonable fit to the treatment arm. Nevertheless, the paf was
identifiable for this trial indicating that the model was able to detect and specify the very limited
potency of the drug. The fact that the drug's potency and clinical efficacy appears to have
increased with introduction of the omicron variant demonstrates a massive challenge for the
therapeutics field: as with vaccines, trials performed when prior variants were circulating may
prove less relevant as new variants continually emerge. A priority should be retesting existing
agents against newly emerging variants in small nimble trials such as PLATCOV, with viral load
endpoints.
426
427 For PLATCOV, the model for the treatment arm matched the trial data precisely and identified
428 the paf. The drug achieved nearly maximal observed viral load reduction in this trial. We
429 identified a similar trend for PANORAMIC. It is notable that the model had the flexibility to
430 account for different viral loads between these trials by predicting more rapid innate immune
431 responses in PLATCOV.
432
We arrived at similar estimated paf in the PLATCOV and PANORAMIC trials, which agreed
when using two separate methods: fitting to individual viral loads and fitting to mean viral load
reduction trial endpoints. This suggests that our approach using in silico cohorts and fitting to
population level outcomes produces reliable results.[11] In many cases, it remains challenging for
academic researchers to obtain individualized data from industry sponsored trials. Therefore, it is
important that the endpoint fitting approach be considered when this is the only data available.
439
Finally, our results highlight challenges in trial design associated with the selection of PCR
assays and the corresponding limits of detection. Each trial reported results with a different limit
of detection which in turn impacts the degree of viral load decrease that can be observed. Initial
viral loads were notably higher in PANORAMIC and MOVe-OUT than PLATCOV. The
equivalent viral loads between PANORAMIC and PLATCOV may reflect a more sensitive PCR
in the PANORAMIC study as past immunity has consistently predicted lower viral loads and
more rapid viral elimination for omicron variants.[12, 34] On the other hand, PANORMIC viral

loads could have been higher than in PLATCOV despite both enrolling omicron infections due to
an older and less healthy population, Ideally, equivalent internationally standardized PCR
quantitation would be used across all trials.
450
Our study has a few limitations. The estimated paf is based on the in vitro assay data against
delta variant in Calu-3 cells. In vitro EC50 is sensitive to assay conditions, including cell type,
the variant of concern, the multiplicity of infection (MOI), and specific lab. In general, the
inability of in vitro assays to match in vivo conditions makes it an unreliable proxy for the in
vivo potency of the drug and explains the necessity of incorporating the paf parameter when
simulating an antiviral clinical trial.
457
In our model, we assumed all mutated viruses are noninfectious. While most drug-induced
random mutations reduce the fitness/viability of the virus, the molnupiravir mutation signature
has been detected in circulating variants, especially in regions where the drug has been used most
commonly.[7] Furthermore, in the PANORAMIC study, no statistical difference was observed
between the rate of culturable samples in the treatment and control arms which implies some
mutated viruses might be transmissible.[35] We justify this assumption in our definition of drug
efficacy. The incomplete efficacy in all three trials may reflect subtherapeutic drug levels but
could also indicate that not all drug-induced mutations not lower viral infectivity.
466
PK parameters were estimated using the data from the plasma concentration of healthy
individuals with the age range of 19-60 (mean 39.6) years old. The clearance rate of renally
cleared drugs often increase with age.[36] This implies that the paf may be larger in an older
population, such as in PANORAMIC participants. Further, we used the plasma concentration in
the PD model to calculate the drug efficacy. However, using the drug's intracellular
concentration with a longer half-life, represented by the central compartment of the PK model,
could also likely lead to a larger estimated paf.
474
475 In summary, we further demonstrate the utility of clinical trial simulation using models that
476 capture drug PK and PD, as well as infection dynamics. In the case of molnupiravir, our results
477 suggest that final viral endpoints should be adjusted based on the drug's mechanism of action.
478
479

Materials and Methods

Study Design.

We developed a viral dynamics model recapitulating viral load data collected from symptomatic individuals in the NBA (National Basketball Association) cohort.[12] We used a two-compartment model to reproduce the PK data of molnupiravir.[19] For clinical trial simulation, we constructed a virtual cohort by randomly selecting 400 individuals from the NBA cohort, matching the trial populations regarding vaccine status and history of infection as closely as possible given cohort characteristics. Due to lack of individual PK data, we used estimated population PK parameters for all individuals in the virtual cohort. The PD parameters for each individual were randomly selected from a log-normal distribution with their means and standard errors estimated based on in vitro assay data. We fit the combined viral dynamic and PKPD model to the average change in viral load from the baseline of the control and treatment arms of three previously published molnupiravir clinical trials.[2-4, 37] Comparing our model to the control arms validated our viral dynamic model and demonstrated how well our virtual cohorts represent the trial control arms. We used the average data from the treatment arms to estimate the potency adjustment factor (paf) by maximizing the R^2 of the fit.[11] We also fit to individual viral load trajectories in PLATCOV and PANORAMIC using the mixed-effect population approach implemented in Monolix[38-40] and obtained both individual paf values and a population distribution.

Viral load data

The NBA cohort dataset published by Hay et al consists of 2875 documented SARS-CoV-2 infections in 2678 people detected through frequent PCR testing regardless of symptoms.[17] We used the viral load data from 1510 infections in 1440 individuals that had at least 4 positive quantitative samples to estimate viral dynamic parameters. We used parameter sets estimated for the symptomatic subpopulation of these individuals to construct virtual cohorts.[12]

Clinical trial data

We used viral load data from three molnupiravir clinical trials. MOVe-OUT by Jayk Bernal et al. included 544 and 549 symptomatic high-risk individuals in the control and treatment arms, respectively.[2] We obtained the average change in viral load data of the control and treatment arms as shared in the supplementary material of their published manuscript in Table S6. Nasal viral load was measured using PCR assay on days 0, 3, 5, 10, and 14 after the treatment start day and adjusted by the baseline viral load. A lower limit of detection (LOD) of 500 copies/ml was used in this trial. The treatment was started within five days of symptom onset.

PLATCOV by Schilling et al. is an open-label, randomized, controlled adaptive trial with 85 and 58 symptomatic, young, healthy individuals in the control and molnupiravir treatment arms, respectively.[4] The oropharyngeal samples from each participant were collected daily on days 0 through 7 and on day 14 after the treatment start day, and viral load was measured using PCR assay. We used the individual viral load data published by the authors for model fitting. From PLATCOV, we averaged over the two oral samples collected from each individual for individual-level viral load fitting, and averaged over all samples collected then calculated viral load drop from baseline for the trial endpoint fitting approach. In both cases, when comparing simulation results with data we used the maximum LOD reported in the published data (~1.26 log).

PANORAMIC is a platform adaptive randomized, controlled trial with 42 and 38 symptomatic, vaccinated individuals with at least one risk factor in the control and treatment arms, respectively.[3] Nasal viral load was measured using PCR and samples were collected on days 0 through 6 and on day 13. We used individual viral load data shared by the authors and adjusted by baseline viral load to obtain mean viral load drop from the baseline. Mean days since symptom onset at baseline (sd) were 2.4 (0.78) for the treatment arm and 2.5(1.12) for the control arm. The lower limit of detection of 100 copies/ml (imputed as 50 copies/ml) was used.

In all three trials, the study participants were treated with 800mg molnupiravir twice per day, for five days.

PK data

Mean plasma concentration data of molnupiravir were obtained by digitizing Figure 3 of the phase I trial by Painter et al. using WebPlotDigitizer.[19] The data used in this paper belong to the multiple-ascending part of the phase I trial where six participants were given 50, 100, 200, 300, 400, 600, and 800 mg of molnupiravir twice daily for 5.5 days, and their plasma concentrations were measured after the first and last doses.

PD data

The data on drug efficacy was obtained from experiments performed at the University of Washington. The efficacy of molnupiravir was measured against the delta variant of SARS-CoV2 in Calu-3 cells (human lung epithelial). Briefly, Calu 3 cells were treated with varying concentrations of molnupiravir prior to infection with SARS-CoV-2 (delta isolate) at a multiplicity of infection of 0.01. Antiviral efficacy and cell viability (of non-infected cells treated with drugs) were assessed as described.[9, 11] There were five replicates per condition, pooled from 2 independent technical experimental repeats (one experiment with triplicate conditions, one experiment in duplicate conditions).

Viral dynamics model

We used data-validated model of SARS-CoV-2 dynamics to model the viral load of symptomatic individuals with SARS-CoV-2 infection.[12] This model assumes that susceptible cells (S) are infected at rate βVS by SARS-CoV-2 virions. The infected cells go through a non-productive eclipse phase (I_E) before producing viruses and transition to becoming productively infected (I_P) at rate κI_E. When encountering productively infected cells, the susceptible cells become refractory to infection (R) at the rate $\phi I_P S$. Refractory cells revert to a susceptible state at rate ρR. The productively infected cells produce virus at the rate πI_P and are cleared at rate δI representing cytolysis and the innate immune response that lacks memory and is proportional to the amount of ongoing infection. If the infection persists longer than time τ, then cytotoxic acquired immunity is activated, which is represented in our model by the rate mI_P. Finally, free virions are cleared at the rate γ. Of note, this model, previously proposed by Ke et al. was selected against other models based on superior fit to data and parsimony.[41] The model written as a set of differential equations has the form,

$$\frac{dS}{dt} = -\beta SV - \phi I_P S + \rho R \qquad\qquad (1a)$$

$$\frac{dR}{dt} = \phi I_P S - \rho R \qquad\qquad (1b)$$

$\quad \frac{dI_E}{dt} = \beta SV - \kappa I_E$ (1c)

$\quad \frac{dI_P}{dt} = \kappa I_E - \delta I_P - m(t) I_P$ (1d)

$\quad \frac{dV}{dt} = \pi I_P - \gamma V$ (1e)

$\quad$ where $\begin{cases} m(t) = 0 & t < \tau \\ m(t) = m & t \geq \tau \end{cases}$ (1f)

To estimate parameter values, we fit the model to viral load data from the NBA cohort using a
mixed-effect population approach implemented in Monolix. Details on the model selection and
fitting process can be found in Owens et al.[12]

We start the simulations with 10^7 susceptible cells. The initial value of the refractory cells is
assumed to be zero since the interferon signaling is not active prior to infection. We further
assume there are no infected cells (eclipse or productive) at the beginning of the infection. We
fix the level of inoculum (V_0) at 97 copies/ml for each individual.

To resolve identifiability issues, we also fixed two parameter values, setting the inverse of the
eclipse phase duration to $\kappa = 4$, and the rate of clearance of virions to $\gamma = 15$.[12]

PK model

We used a two-compartmental PK model which includes the amount of drug in the GI tract
(A_{GI}), the plasma compartment (A_p), and the respiratory tract (A_L). The drug is administered
orally, passes through the GI tract and gets absorbed into the blood at the rate κ_a. The drug then
transfers from the blood into the peripheral compartment (or the respiratory tract) at the rate κ_{PL}.
The metabolized drug transfers back into the plasma at the rate κ_{LP} from where it clears from the
body at the rate κ_{CL}. The model in the form of ordinary differential equations is written as,

$\quad \frac{dA_{GI}}{dt} = -\kappa_a A_{GI}$ (2a)

$\quad \frac{dA_P}{dt} = \kappa_a A_{GI} + \kappa_{LP} A_L - (\kappa_{CL} + \kappa_{PL}) A_P$ (2b)

$\quad \frac{dA_L}{dt} = \kappa_{PL} A_P - \kappa_{LP} A_L$ (2c)

We used Monolix and a mixed-effect population approach to estimate the parameters and their
standard deviations. With the initial condition of ($A_{GI} =$ Dose, $A_p = 0$, $A_L = 0$); we fit $C_P = \frac{A_P}{Vol}$
to the plasma concentration data where Vol is the estimated plasma volume. Details on
parameter values and the error model provided in **Table S1**.

PD model

For the pharmacodynamics model we used Hill equation, $\epsilon(t) = \frac{E_{max} C(t)^n}{C(t)^n + EC_{50}^n}$, where $C(t)$ is the
drug concentration in plasma, E_{max} is the maximum efficacy, n is the Hill coefficient, and EC_{50}
is the drug concentration in plasma required for 50% efficacy. We used least-squared fitting to

obtain the three parameters ($E_{max}, n,$ and EC_{50}) and their standard deviations. The average drug
efficacy over the treatment period is calculated using the formula,

$\quad E_{ave} = \frac{1}{t_{start}-t_{end}} \int_{t_{start}}^{t_{end}} \epsilon(t)dt \qquad\qquad (3)$

Where t_{start} and t_{end} are the treatment start day and end day, respectively.

603 Combined PKPD and VL models

The plasma concentration of molnupiravir obtained from the PK model is used in the PD model
to obtain time-dependent efficacy. Since molnupiravir imposes lethal mutations during the viral
replication process, in our model, a portion of all viruses produced by an infected cell, measured
by $\epsilon(t)$, are mutated (V_m) and therefore assumed to be non-infectious, with the addition that most
detected viral RNA pre-treatment is also non-infectious. The production rate of non-mutated
viruses is decreased by a factor of $(1 - \epsilon(t))$. Equation 1e is written as,

$\quad \frac{dV}{dt} = (1 - \epsilon(t))\pi I_P - \gamma V \qquad\qquad (4a)$

$\quad \frac{dV_m}{dt} = \epsilon(t)\pi I_P - \gamma V_m \qquad\qquad (4b)$

Total viral load ($V + V_m$) is used to fit the PCR assay data from each trial.

613 Fitting the combined model to individual viral load data in the PLATCOV trial

We used the population mixed-effect approach implemented in Monolix to estimate each
individual's viral dynamics parameters and the potency adjustment factor (paf). Due to the lack
of data from the initial phase of infection in the PLATCOV and PANORAMIC trials, we include
the data from Omicron-infected individuals in the NBA cohort in the fitting populationto inform
the model about the initial phase of infection. We fixed the PK parameters to the estimated
population values (**Table S1**), and the PD parameters other than EC50 to the in vitro estimated
population values (**Table S2**). We used the study category (NBA vs PLATCOV and
PANORAMIC) as a covariate for t_0 (timing of infection) and τ (timing of the adaptive immune
response) since the first recorded positive test is likely much later for the clinical trials. In the
NBA study, samples were collected almost daily regardless of symptoms often leading to pre-
symptomatic detection, while in the two clinical trials, the baseline measurement occurred after
symptom onset, trial enrollment and consent.

626 Construction of a virtual cohort

To generate a cohort for our simulated clinical trials, we randomly selected 400 individuals (for
each arm) from the unvaccinated symptomatic subpopulation of the NBA cohort for MOVe-
OUT and the vaccinated, Omicron infected subpopulation for PLATCOV and PANORAMIC
and used their individual viral load parameters estimated by fitting our viral dynamics model to
the data. A sample size of n=400 (out of 822 vaccinated individuals with Omicron infection) was
used to mimic a large-scale clinical trial and maintain relatively low overlap between virtual
cohorts used in each arm of the simulations and between different simulations. Since the time of
symptom onset is not available for all individuals in the NBA data, we randomly drew an
incubation period for each individual from gamma distributions with variant-specific parameters
estimated by Gamiche et al.[42] The start of treatment relative to symptom onset was randomly

selected according to a uniform distribution for MOVe-OUT and PLATCOV, and a logit normal
distribution for PANORAMIC with limits of [0,5] days and mean and standard deviation
reported in the PANORAMIC trial for control and treatment arms. The same population PK
parameters were assigned to each individual. The relevant dose in each scenario was added to the
A_{GI} compartment (the absorption equation) of the PK model (**eq 2a**) at each dosing timepoint
(t=0, 0.5, 1, 1.5, …., 4.5 days). For each dose, the appropriate PK parameter were used (**Table
S1**). PD parameters were also randomly drawn from a log-normal distribution with the estimated
mean and standard deviation. The standard deviation of the PD parameters represents the
accuracy of the assays and not individual variability.

Potency adjustment factor (paf)

647 The paf is defined as,

$$\text{paf} = \frac{EC_{50,in\ vivo}}{EC_{50,in\ vitro}} \tag{5}$$

650 We estimated the paf by maximizing R^2 when fitting the change in viral load of the treatment
651 arm of our simulation to the change in viral load observed in the treatment arm of the clinical
652 trial on day 0 through day 7.

Measuring rebound probability

655 A viral load rebound in the treatment arm was defined when the viral load at any time after
656 treatment ended exceeded the viral load at the end of the treatment by ≥ 1 on a $\log_{10}$ scale. In the
657 control group, viral rebound was defined in patients who had at least two peaks with minimum
658 height of 1000 copies/ml in their viral load trajectories and the second peak was ≥ 1 log higher
659 than its preceding local minimum.

Software:

662 All the model fittings in this study were performed using Monolix version 2023R1.

663 The data analysis and simulations were performed using Python 3.9.12.

Data availability:

The data analyzed in this work was previously published by Hay et al., Schilling et al. and
Standing et al., and is available at:

https://github.com/gradlab/SC2-kinetics-immune-history and
https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0

https://zenodo.org/records/10375295

Pharmacodynamics data is available on GitHub at
https://github.com/sEsmaeili/MolnupiravirModeling
672
Code availability:

All codes and materials used in the analysis are available on GitHub

https://github.com/sEsmaeili/MolnupiravirModeling

Funding:

This work is supported by NIAID R01AI77512-01 (JTS, SP).

Author Contributions:

Conceptualization: JTS, SE, KO

Methodology: JTS, SE, KO

Software: SE, KO

Investigation: JTS, SE, SJP, JW

Formal analysis: SE

Writing – original draft: JTS, SE

Writing – review & editing: JTS, SE, KO, SJP, JFS, DML, SZ, JAW, WHKS,

689
690

References

1.   Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model. J Infect Dis. 2021;224(5):749-53. doi: 10.1093/infdis/jiab361. PubMed PMID: 34244768; PMCID: PMC8408768.

2.   Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, Martín-Quirós A, Caraco Y, Williams-Diaz A, Brown ML, Du J, Pedley A, Assaid C, Strizki J, Grobler JA, Shamsuddin HH, Tipping R, Wan H, Paschke A, ..., Group M-OS. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509-20. Epub 20211216. doi: 10.1056/NEJMoa2116044. PubMed PMID: 34914868; PMCID: PMC8693688.

3.   Butler CC, Hobbs FDR, Gbinigie OA, Rahman NM, Hayward G, Richards DB, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Nguyen-Van-Tam JS, Patel MG, Saville BR, Marion J, Ogburn E, Allen J, ..., Group PTC. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2023;401(10373):281-93. Epub 20221222. doi: 10.1016/S0140-6736(22)02597-1. PubMed PMID: 36566761; PMCID: PMC9779781.

4.   Schilling WHK, Jittamala P, Watson JA, Boyd S, Luvira V, Siripoon T, Ngamprasertchai T, Batty EM, Cruz C, Callery JJ, Singh S, Saroj M, Kruabkontho V, Ngernseng T, Tanglakmankhong N, Tubprasert J, Abdad MY, Madmanee W, Kouhathong J, ..., Group PC. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. Lancet Infect Dis. 2024;24(1):36-45. Epub 20230928. doi: 10.1016/S1473-3099(23)00493-0. PubMed PMID: 37778363; PMCID: PMC7615401.

5.   Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R, Rusnak JM, Investigators E-H. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397-408. Epub 20220216. doi: 10.1056/NEJMoa2118542. PubMed PMID: 35172054; PMCID: PMC8908851.

6.   Fountain-Jones NM, Vanhaeften R, Williamson J, Maskell J, Chua IJ, Charleston M, Cooley L. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study. Lancet Microbe. 2024;5(5):e452-e8. Epub 20240322. doi: 10.1016/S2666-5247(23)00393-2. PubMed PMID: 38527471.

7.   Sanderson T, Hisner R, Donovan-Banfield I, Hartman H, Løchen A, Peacock TP, Ruis C. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature. 2023;623(7987):594-600. Epub 20230925. doi: 10.1038/s41586-023-06649-6. PubMed PMID: 37748513; PMCID: PMC10651478.

8.   Rosenke K, Lewis MC, Feldmann F, Bohrnsen E, Schwarz B, Okumura A, Bohler WF, Callison J, Shaia C, Bosio CM, Lovaglio J, Saturday G, Jarvis MA, Feldmann H. Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques. JCI Insight. 2023;8(4). Epub 20230222. doi: 10.1172/jci.insight.166485. PubMed PMID: 36574296; PMCID: PMC9977490.

9.   Wagoner J, Herring S, Hsiang TY, Ianevski A, Biering SB, Xu S, Hoffmann M, Pöhlmann S, Gale M, Aittokallio T, Schiffer JT, White JM, Polyak SJ. Combinations of Host-

and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiol Spectr. 2022;10(5):e0333122. Epub 20221003. doi: 10.1128/spectrum.03331-22. PubMed PMID: 36190406; PMCID: PMC9718484.

10.   Cox RM, Lieber CM, Wolf JD, Karimi A, Lieberman NAP, Sticher ZM, Roychoudhury P, Andrews MK, Krueger RE, Natchus MG, Painter GR, Kolykhalov AA, Greninger AL, Plemper RK. Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models. Nat Commun. 2023;14(1):4731. Epub 20230807. doi: 10.1038/s41467-023-40556-8. PubMed PMID: 37550333; PMCID: PMC10406822.

11.   Esmaeili S, Owens K, Wagoner J, Polyak SJ, White JM, Schiffer JT. A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy. Nat Commun. 2024;15(1):5478. Epub 20240628. doi: 10.1038/s41467-024-49458-9. PubMed PMID: 38942778; PMCID: PMC11213957.

12.   Owens K, Esmaeili S, Schiffer JT. Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses. JCI Insight. 2024;9(9). Epub 20240404. doi: 10.1172/jci.insight.176286. PubMed PMID: 38573774; PMCID: PMC11141931.

13.   Edelstein GE, Boucau J, Uddin R, Marino C, Liew MY, Barry M, Choudhary MC, Gilbert RF, Reynolds Z, Li Y, Tien D, Sagar S, Vyas TD, Kawano Y, Sparks JA, Hammond SP, Wallace Z, Vyas JM, Barczak AK, ..., Siedner MJ. SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study. Ann Intern Med. 2023;176(12):1577-85. Epub 20231114. doi: 10.7326/M23-1756. PubMed PMID: 37956428; PMCID: PMC10644265.

14.   Harrington PR, Cong J, Troy SB, Rawson JMO, O'Rear JJ, Valappil TI, McGarry Connelly S, Farley J, Birnkrant D. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023;72(51):1365-70. Epub 20231222. doi: 10.15585/mmwr.mm7251a2. PubMed PMID: 38127674; PMCID: PMC10754264.

15.   Anderson AS, Caubel P, Rusnak JM, Investigators E-HT. Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19. N Engl J Med. 2022;387(11):1047-9. Epub 20220907. doi: 10.1056/NEJMc2205944. PubMed PMID: 36069818; PMCID: PMC9513855.

16.   Perelson AS, Ribeiro RM, Phan T. An explanation for SARS-CoV-2 rebound after Paxlovid treatment. medRxiv. 2023:2023.05.30.23290747. doi: 10.1101/2023.05.30.23290747.

17.   Hay JA, Kissler SM, Fauver JR, Mack C, Tai CG, Samant RM, Connolly S, Anderson DJ, Khullar G, MacKay M, Patel M, Kelly S, Manhertz A, Eiter I, Salgado D, Baker T, Howard B, Dudley JT, Mason CE, ..., Grad YH. Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: A retrospective cohort study. Elife. 2022;11. Epub 20221116. doi: 10.7554/eLife.81849. PubMed PMID: 36383192; PMCID: PMC9711520.

18.   Clairon Q, Pasin C, Balelli I, Thiébaut R, Prague M. Parameter estimation in nonlinear mixed effect models based on ordinary differential equations: an optimal control approach. Computational Statistics. 2023. doi: 10.1007/s00180-023-01420-x.

19.   Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, Morin MJ, Szewczyk LJ, Painter GR. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5). Epub 20210301. doi: 10.1128/AAC.02428-20. PubMed PMID: 33649113; PMCID: PMC8092915.

20.   Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E,
Anderson KS, Acosta EP, Siliciano RF. Dose-response curve slope sets class-specific limits on
inhibitory potential of anti-HIV drugs. Nature Medicine. 2008;14(7):762-6. doi:
10.1038/nm1777.
21.   Zhou S, Long N, Rosenke K, Jarvis MA, Feldmann H, Swanstrom R. Combined
Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced
Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations. J Infect
Dis. 2024. Epub 20240708. doi: 10.1093/infdis/jiae213. PubMed PMID: 38973065.
22.   Schiffer JT, Swan DA, Corey L, Wald A. Rapid viral expansion and short drug half-life
explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents.
Antimicrob Agents Chemother. 2013;57(12):5820-9. Epub 2013/09/11. doi:
10.1128/AAC.01114-13. PubMed PMID: 24018260; PMCID: PMC3837890.
23.   Schiffer JT, Swan DA, Magaret A, Corey L, Wald A, Ossig J, Ruebsamen-Schaeff H,
Stoelben S, Timmler B, Zimmermann H, Melhem MR, Van Wart SA, Rubino CM, Birkmann A.
Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial
outcomes. Sci Transl Med. 2016;8(324):324ra15. Epub 2016/02/05. doi:
10.1126/scitranslmed.aad6654. PubMed PMID: 26843190; PMCID: PMC4880060.
24.   Backer JA, Eggink D, Andeweg SP, Veldhuijzen IK, van Maarseveen N, Vermaas K,
Vlaemynck B, Schepers R, van den Hof S, Reusken CB, Wallinga J. Shorter serial intervals in
SARS-CoV-2 cases with Omicron BA.1 variant compared with Delta variant, the Netherlands,
13 to 26 December 2021. Euro Surveill. 2022;27(6). doi: 10.2807/1560-
7917.ES.2022.27.6.2200042. PubMed PMID: 35144721; PMCID: PMC8832521.
25.   Wu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused
by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. JAMA Netw Open.
2022;5(8):e2228008. Epub 20220801. doi: 10.1001/jamanetworkopen.2022.28008. PubMed
PMID: 35994285; PMCID: PMC9396366.
26.   Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ,
Peppelenbosch MP, Haagmans BL, Pan Q. SARS-CoV-2 Omicron variant is highly sensitive to
molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32(3):322-4. Epub 20220120.
doi: 10.1038/s41422-022-00618-w. PubMed PMID: 35058606; PMCID: PMC8771185.
27.   Yotsuyanagi H, Ohmagari N, Doi Y, Yamato M, Bac NH, Cha BK, Imamura T, Sonoyama
T, Ichihashi G, Sanaki T, Tsuge Y, Uehara T, Mukae H. Efficacy and Safety of 5-Day Oral
Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized
Clinical Trial. JAMA Netw Open. 2024;7(2):e2354991. Epub 20240205. doi:
10.1001/jamanetworkopen.2023.54991. PubMed PMID: 38335000; PMCID: PMC10858401.
28.   Cruciani M, Pati I, Masiello F, Piccinini V, Pupella S, De Angelis V. SARS-CoV-2
infection rebound among patients receiving antiviral agents, convalescent plasma, or no
treatment: a systematic review with meta-analysis. Blood Transfus. 2024. Epub 20240527. doi:
10.2450/BloodTransfus.764. PubMed PMID: 38814880.
29.   Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska
M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen
P, Morris L, Mkhize NN, Williamson C, Mullins JI, ..., Edupuganti S. High monoclonal
neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated
Prevention trials. Nat Commun. 2023;14(1):8299. Epub 20231214. doi: 10.1038/s41467-023-
43384-y. PubMed PMID: 38097552; PMCID: PMC10721814.

30.   Reeves DB, Gaebler C, Oliveira TY, Peluso MJ, Schiffer JT, Cohn LB, Deeks SG, Nussenzweig MC. Impact of misclassified defective proviruses on HIV reservoir measurements. Nat Commun. 2023;14(1):4186. Epub 20230713. doi: 10.1038/s41467-023-39837-z. PubMed PMID: 37443365; PMCID: PMC10345136.

31.   Schiffer JT, Corey L. Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat Med. 2013;19(3):280-90. Epub 2013/03/08. doi: 10.1038/nm.3103. PubMed PMID: 23467247; PMCID: PMC3981536.

32.   Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A. 2010;107(44):18973-8. Epub 2010/10/20. doi: 10.1073/pnas.1006614107. PubMed PMID: 20956313; PMCID: PMC2973882.

33.   Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, Musser BJ, Soo Y, Rofail D, Im J, Perry C, Pan C, Hosain R, Mahmood A, Davis JD, Turner KC, Hooper AT, Hamilton JD, Baum A, ..., Investigators T. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021;384(3):238-51. Epub 20201217. doi: 10.1056/NEJMoa2035002. PubMed PMID: 33332778; PMCID: PMC7781102.

34.   Watson JA, Kissler SM, Day NPJ, Grad YH, White NJ. Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies. Antimicrob Agents Chemother. 2022;66(7):e0019222. Epub 20220623. doi: 10.1128/aac.00192-22. PubMed PMID: 35736134; PMCID: PMC9295592.

35.   Standing JF, Buggiotti L, Guerra-Assuncao JA, Woodall M, Ellis S, Agyeman AA, Miller C, Okechukwu M, Kirkpatrick E, Jacobs AI, Williams CA, Roy S, Martin-Bernal LM, Williams R, Smith CM, Sanderson T, Ashford FB, Emmanuel B, Afzal ZM, ..., Group PV. Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients. Nat Commun. 2024;15(1):1652. Epub 20240223. doi: 10.1038/s41467-024-45641-0. PubMed PMID: 38396069; PMCID: PMC10891158.

36.   Lonsdale DO, Kipper K, Baker EH, Barker CIS, Oldfield I, Philips BJ, Johnston A, Rhodes A, Sharland M, Standing JF. β-Lactam antimicrobial pharmacokinetics and target attainment in critically ill patients aged 1 day to 90 years: the ABDose study. J Antimicrob Chemother. 2020;75(12):3625-34. doi: 10.1093/jac/dkaa363. PubMed PMID: 32989452.

37.   Singh S, Boyd S, Schilling WHK, Watson JA, Mukaka M, White NJ. The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis. J Antimicrob Chemother. 2024. Epub 20240222. doi: 10.1093/jac/dkae045. PubMed PMID: 38385479.

38.   Prague M, Lavielle M. SAMBA: A novel method for fast automatic model building in nonlinear mixed-effects models. CPT Pharmacometrics Syst Pharmacol. 2022;11(2):161-72. Epub 20220201. doi: 10.1002/psp4.12742. PubMed PMID: 35104058; PMCID: PMC8846636.

39.   Bing A, Hu Y, Prague M, Hill AL, Li JZ, Bosch RJ, De Gruttola V, Wang R. Comparison of empirical and dynamic models for HIV viral load rebound after treatment interruption. Stat Commun Infect Dis. 2020;12(Suppl 1). Epub 20200821. doi: 10.1515/scid-2019-0021. PubMed PMID: 34158910; PMCID: PMC8216669.

40.   Chan PL, Jacqmin P, Lavielle M, McFadyen L, Weatherley B. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. J Pharmacokinet Pharmacodyn. 2011;38(1):41-61. Epub 2010/11/19. doi: 10.1007/s10928-010-9175-z. PubMed PMID: 21088872; PMCID: PMC3020311.

41. Ke R, Zitzmann C, Ho DD, Ribeiro RM, Perelson AS. In vivo kinetics of SARS-CoV-2
infection and its relationship with a person's infectiousness. Proc Natl Acad Sci U S A.
2021;118(49). doi: 10.1073/pnas.2111477118. PubMed PMID: 34857628.
42. Galmiche S, Cortier T, Charmet T, Schaeffer L, Chény O, von Platen C, Lévy A, Martin
S, Omar F, David C, Mailles A, Carrat F, Cauchemez S, Fontanet A. SARS-CoV-2 incubation
period across variants of concern, individual factors, and circumstances of infection in France: a
case series analysis from the ComCor study. Lancet Microbe. 2023;4(6):e409-e17. Epub
20230418. doi: 10.1016/S2666-5247(23)00005-8. PubMed PMID: 37084751; PMCID:
PMC10112864.
882

883